No Data
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
PuraPharm Corp. Ltd. Announces Auditor Change
Hong Kong's Department of Health: To develop Hong Kong into a gateway for the internationalization of traditional Chinese medicine and Chinese herbal medicine.
Secretary for Food and Health of the Hong Kong Special Administrative Region, Dr. Constance Chan, stated that in order to promote the standardization and internationalization of traditional chinese medicine, Hong Kong aims to become a gateway for the internationalization of traditional chinese medicine.
Purapharm collaborates with EC Healthcare to hold a 'Pink October' charity clinic, promoting the innovation of integrated Chinese and Western medical models.
Hong Kong, 7th November 2024 / PRNewswire / - Purapharm Group (1498.HK) and EC Healthcare (2138.HK) jointly organized the "Pink October: Integrating East and West, Breast Cancer Prevention Charity Event" in October, providing professional consultation services combining traditional Chinese medicine and Western medicine for breast cancer and other cancer patients. This event is not only an important milestone in the initiation of strategic cooperation between the two parties, but also a innovative move to promote the development of collaboration between traditional Chinese medicine and Western medicine, and to advance the modernization of traditional Chinese medicine. The event has received support from the Global Chinese Breast Cancer Organizations Alliance, Hong Kong Nurses Association, Alone_In_This_War Foundation and Hong Kong Academy of Nursing among many others.
PuraPharm Corp. Plans Major Capital Restructuring
Purapharm (01498.HK) recommends reducing its share capital and splitting the unissued shares.
Gelonghui November 1st | Purapharm (01498.HK) announced that the company proposed to implement a reduction and subdivision of its share capital, involving the cancellation of 0.099 US dollars per share of issued common stock in full amount of share capital, reducing the face value of issued common stock from 0.1 US dollars to 0.001 US dollars per share. The statutory but unissued common stock with a face value of 0.1 US dollars per share will be subdivided into 100 shares of new common stock with a face value of 0.001 US dollars per share, and after the reduction and subdivision, the issued common stock with a face value of 0.001 US dollars per share in the company's share capital will become one new common stock, and each share with a face value of 0.
No Data
